Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Dexametasona para direcionar o estresse e os mecanismos do sistema imunológico subjacentes ao desejo por álcool

28 de setembro de 2026 atualizado por: Helen Fox, Stony Brook University

Dexametasona para direcionar o estresse e as alterações do sistema imunológico durante a abstinência precoce em indivíduos com transtorno por uso de álcool (AUD)

This is a double-blind, placebo-controlled, proof of concept laboratory study to recruit N=70 (35 Males / 35 Females) non-treatment seeking, heavy drinkers with alcohol use disorder (AUD). It is hypothesized that randomization to 1.5mgs dexamethasone versus placebo will decrease alcohol craving during stress by decreasing basal cortisol, increasing anti-inflammatory cytokine levels and potentially normalizing the immune response to stress.

Visão geral do estudo

Status

Concluído

Tipo de estudo

Intervencional

Inscrição (Real)

27

Estágio

  • Fase inicial 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • New York
      • Stony Brook, New York, Estados Unidos, 11794
        • The Health Sciences Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 55 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Non-treatment seeking heavy drinking men and women with AUD
  • Age range 18-55,
  • Body Mass Index (BMI) of 18-35
  • Positive ethylglucuronide (EtG) urine toxicology screen for alcohol
  • Able to provide informed written and verbal consent
  • Able to read English and complete study evaluations
  • Good health as verified by screening examination.

Exclusion Criteria:

  • Meet criteria for Substance Use Disorder (SUD) or other psychoactive substances, excluding nicotine
  • Unable to remain abstinent for five days
  • Need for a medically assisted detoxification
  • Regular use of steroids, anticonvulsants, sedatives/hypnotics, prescription analgesics, other anti-hypertensives, anti-arrythmics, antiretroviral medications, tricyclic antidepressants, naltrexone, disulfiram, and any other psychoactive medications with the exception of stabilization on Selective Serotonin Re-uptake Inhibitors (SSRIs)
  • Psychotic or severely psychiatrically disabled
  • Significant underlying medical conditions which would be of potential harm
  • Pregnancy or breast feeding women;
  • Women using monophasic contraceptives
  • Electrocardiogram (EKG) evidence of clinically significant conduction abnormalities, (Bazlett's corrected QT (QTc) interval of >450 msec for men and QTc>470 msec for women).

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Guanfacine

single dose of dexamethasone (1.5mg) administered orally

1.5mg oral dexamethasone to be administered once at 11:00PM

Outros nomes:
  • Decadron, Dexametasona Intensol, Dexasone, Solurex e Baycadron.
Comparador de Placebo: Placebo

single dose of placebo administered orally

oral placebo to be administered once at 11:00PM

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Alcohol craving as assessed using subjective report following stress exposure
Prazo: Change from baseline to +5 minutes following stress exposure

The 8-item Alcohol Urges Questionnaire (AUQ) will be used to measure alcohol craving. There are 8 items, each with a Likert scale response from 1 to 7 (1: Strongly Disagree, 7: Strongly Agree). Total possible score of 56. The higher the score the higher the alcohol craving

Change from baseline to +5 minutes following stress exposure
Alcohol craving as assessed using subjective report following stress exposure
Prazo: Change from baseline to +15 minutes following stress exposure

The 8-item Alcohol Urges Questionnaire (AUQ) will be used to measure alcohol craving. There are 8 items, each with a Likert scale response from 1 to 7 (1: Strongly Disagree, 7: Strongly Agree). Total possible score of 56. The higher the score the higher the alcohol craving

Change from baseline to +15 minutes following stress exposure
Alcohol craving as assessed using subjective report following stress exposure
Prazo: Change from baseline to +30 minutes following stress exposure

The 8-item Alcohol Urges Questionnaire (AUQ) will be used to measure alcohol craving. There are 8 items, each with a Likert scale response from 1 to 7 (1: Strongly Disagree, 7: Strongly Agree). Total possible score of 56. The higher the score the higher the alcohol craving

Change from baseline to +30 minutes following stress exposure
Alcohol craving as assessed using subjective report following stress exposure
Prazo: Change from baseline to +5 minutes following stress exposure

A visual analog scale will be used to measure alcohol craving. Participants will be required to rate "how much they are craving alcohol right at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely)

Change from baseline to +5 minutes following stress exposure
Alcohol craving as assessed using subjective report following stress exposure
Prazo: Change from baseline to +15 minutes following stress exposure

A visual analog scale will be used to measure alcohol craving. Participants will be required to rate "how much they are craving alcohol right at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely)

Change from baseline to +15 minutes following stress exposure
Alcohol craving as assessed using subjective report following stress exposure
Prazo: Change from baseline to +30 minutes following stress exposure

A visual analog scale will be used to measure alcohol craving. Participants will be required to rate "how much they are craving alcohol right at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely)

Change from baseline to +30 minutes following stress exposure
Hypothalamic-Pituitary-Adrenal (HPA)-axis response to stress exposure as assessed by cortisol
Prazo: Change from baseline to +5 minutes following stress exposure

4mls of plasma cortisol will be collected following exposure to stress

Change from baseline to +5 minutes following stress exposure
HPA axis response to stress exposure as assessed by cortisol
Prazo: Change from baseline to +15 minutes following stress exposure

4mls of plasma cortisol will be collected following exposure to stress

Change from baseline to +15 minutes following stress exposure
HPA axis response to stress exposure as assessed by cortisol
Prazo: Change from baseline to +30 minutes following stress exposure

4mls of plasma cortisol will be collected following exposure to stress

Change from baseline to +30 minutes following stress exposure
HPA axis response to stress exposure as assessed by Adrenocorticotropic Hormone (ACTH)
Prazo: Change from baseline to +5 minutes following stress exposure

4mls of plasma ACTH will be collected following exposure to stress

Change from baseline to +5 minutes following stress exposure
HPA axis response to stress exposure as assessed by ACTH
Prazo: Change from baseline to +15 minutes following stress exposure

4mls of plasma ACTH will be collected following exposure to stress

Change from baseline to +15 minutes following stress exposure
HPA axis response to stress exposure as assessed by ACTH
Prazo: Change from baseline to +30 minutes following stress exposure

4mls of plasma ACTH will be collected following exposure to stress

Change from baseline to +30 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Prazo: Change from baseline to +5 minutes following stress exposure

4mls of plasma Interleukin (IL)-10 will be collected following exposure to stress

Change from baseline to +5 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Prazo: Change from baseline to +15 minutes following stress exposure

4mls of plasma IL-10 will be collected following exposure to stress

Change from baseline to +15 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Prazo: Change from baseline to +30 minutes following stress exposure

4mls of plasma IL-10 will be collected following exposure to stress

Change from baseline to +30 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Prazo: Change from baseline to +5 minutes following stress exposure

4mls of plasma Interleukin 1 receptor antagonist (IL1-ra) will be collected following exposure to stress

Change from baseline to +5 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Prazo: Change from baseline to +15 minutes following stress exposure

4mls of plasma IL1-ra will be collected following exposure to stress

Change from baseline to +15 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Prazo: Change from baseline to +30 minutes following stress exposure

4mls of plasma IL1-ra will be collected following exposure to stress

Change from baseline to +30 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Prazo: Change from baseline to +5 minutes following stress exposure

4mls of plasma IL-6 will be collected following exposure to stress

Change from baseline to +5 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Prazo: Change from baseline to +15 minutes following stress exposure

4mls of plasma IL-6 will be collected following exposure to stress

Change from baseline to +15 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Prazo: Change from baseline to +30 minutes following stress exposure

4mls of plasma IL-6 will be collected following exposure to stress

Change from baseline to +30 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Prazo: Change from baseline to +5 minutes following stress exposure

4mls of plasma Tumor Necrosis Factor alpha (TNFa) will be collected following exposure to stress

Change from baseline to +5 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Prazo: Change from baseline to +15 minutes following stress exposure

4mls of plasma TNFa will be collected following exposure to stress

Change from baseline to +15 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Prazo: Change from baseline to +30 minutes following stress exposure

4mls of plasma TNFa will be collected following exposure to stress

Change from baseline to +30 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Prazo: Change from baseline to +5 minutes following stress exposure

4mls of plasma Tumor Necrosis Factor Receptor 1 (TNFR1) will be collected following exposure to stress

Change from baseline to +5 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Prazo: Change from baseline to +15 minutes following stress exposure

4mls of plasma TNFR1 will be collected following exposure to stress

Change from baseline to +15 minutes following stress exposure
Immune system response to stress exposure as assessed by peripheral cytokines
Prazo: Change from baseline to +30 minutes following stress exposure

4mls of plasma TNFR1 will be collected following exposure to stress

Change from baseline to +30 minutes following stress exposure

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Anxiety as assessed using subjective report following stress exposure
Prazo: Change from baseline to +5 minutes following stress exposure

A visual analog scale will be used to measure anxiety. Participants will be required to rate "how nervous, anxious or jittery they are feeling at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely)

Change from baseline to +5 minutes following stress exposure
Anxiety as assessed using subjective report following stress exposure
Prazo: Change from baseline to +15 minutes following stress exposure

A visual analog scale will be used to measure anxiety. Participants will be required to rate "how nervous, anxious or jittery they are feeling at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely)

Change from baseline to +15 minutes following stress exposure
Anxiety as assessed using subjective report following stress exposure
Prazo: Change from baseline to +30 minutes following stress exposure

A visual analog scale will be used to measure anxiety. Participants will be required to rate "how nervous, anxious or jittery they are feeling at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely)

Change from baseline to +30 minutes following stress exposure
Negative Mood as assessed using subjective report following stress exposure
Prazo: Change from baseline to +5 minutes following stress exposure

The Differential Emotion Scale will be used to measure negative mood. Participants will be required to rate on a 5-point scale the extent to which an emotional word describes the way they feel at the current time. 1: not at all, 5: Extremely

Change from baseline to +5 minutes following stress exposure
Negative Mood as assessed using subjective report following stress exposure
Prazo: Change from baseline to +15 minutes following stress exposure

The Differential Emotion Scale will be used to measure negative mood. Participants will be required to rate on a 5-point scale the extent to which an emotional word describes the way they feel at the current time. 1: not at all, 5: Extremely

Change from baseline to +15 minutes following stress exposure
Negative Mood as assessed using subjective report following stress exposure
Prazo: Change from baseline to +30 minutes following stress exposure

The Differential Emotion Scale will be used to measure negative mood. Participants will be required to rate on a 5-point scale the extent to which an emotional word describes the way they feel at the current time. 1: not at all, 5: Extremely

Change from baseline to +30 minutes following stress exposure

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Helen C Fox, PhD, Indiana University School of Medicine, Dept. of Psychiatry

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

11 de março de 2022

Conclusão Primária (Real)

23 de junho de 2024

Conclusão do estudo (Real)

30 de junho de 2024

Datas de inscrição no estudo

Enviado pela primeira vez

22 de março de 2022

Enviado pela primeira vez que atendeu aos critérios de CQ

22 de março de 2022

Primeira postagem (Real)

31 de março de 2022

Atualizações de registro de estudo

Última Atualização Postada (Real)

2 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

28 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever